|
Country: Japan
City: Nara
IHTC:
Nara Hemophilia Centre
Nara Medical University
Department of Pediatrics, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
Tel.: 81 744 29 8881
Fax: 81 744 24 9222
Email: ayped@naramed-u.ac.jp
Website: www.naramed-u.ac.jp/~ped/
Director: Midori Shima
Responsible for training: Midori Shima
Fellowship logistics coordinator: M. Shima
Year of IHTC designation: 1998
Areas of specialty: General hemophilia care; pediatrics; orthopedic surgery; laboratory diagnosis (not genetics); genetic diagnosis. Genetic counseling.
DESCRIPTION OF TRAINING PROGRAM
Clinical activities: Nara Medical University, located in central Japan, is the biggest hemophilia center in the western part of Japan. Approximately 500 patients with hemophilia A, 100 with hemophilia B, 150 with von Willebrand disease and 80 with other congenital bleeding and thrombotic discorders are registered. All services concerning hemophilia comprehensive care are offered, including diagnosis, treatment, counselling and an educational program for home infusion. Professor Yoshioka organizes all these activities. Our centre also provides HIV/ AIDS clinics.
Laboratory activities/research: There is a coagulation laboratory for diagnosis and management of patients with congenital and acquired bleeding and thrombotic disorders. The laboratory also has responsibilities for nationwide pre- and post–marketing surveillance of factor VIII, IX and vWF products. Molecular diagnosis/analysis of hemophilia A and B and von Willebrand is one of the important activities in our laboratory. Main research projects are studies on structure and function of factor VIII/von Willebrand factor and other clotting factors, mechanism of thrombus formation, and immunological and biochemical analysis of inhibitor development.
Multidisciplinary activities/research: Dr. Y. Tanaka, Dept. of Orthopedic Surgery, has successfully performed numerous surgeries involving hemophilic joints.
Additional information: A sister-school relationship between Chiang Mai University in Thailand and Nara Medical University started in 1997. Our hemophilia centre accepted one PhD from Shanghai Children’s Institute through a Japan-China Medical Exchange Program and one MD from Bangkok, Thailand. The centre can train one fellow annually.
DESCRIPTION OF IHTC FACILITIES
Location: Nara Hemophilia Center/Nara Medical University is situated in Kashihara, Nara, Japan, which is a city of approximately 0.2 million inhabitants. Kashihara is located in the centre of Nara Prefecture, which is an ancient capital of Japan and designated as a World Heritage area by UNESCO.
Climate:The climate is temperate, with a little snow in winter and hot in summer.
Accommodation (residence, meals, etc...): A guest house is available nearby at reasonable rates, with cafeteria facilities within the hospital. The cost of living is less expensive than in major cosmopolitan cities, e. g., Tokyo, New York, Paris. Languages spoken include Japanese and English.
Transportation: It takes one hour by limousine bus from Osaka International Airport (KIX)
Language: English, Japanese
Financial assistance: Dependent on WFH funds.
Cost of living (per week): 200 USD
Communications tools for trainees: Computer, Internet access.
RELEVANT PUBLICATIONS BY IHTC STAFF
Yoshioka A, Fukutake K, Takamatsu J, Shirahata A, and the Kogenate Post-Marketing Surveillance Study Group. Clinical Evaluation of Recombinant Factor VIII Preparation (Kogenate) in Previously Treated Patients with Hemophilia A: Descriptive Meta-Analysis of Post-Marketing Study Data. Int. J Hematol. 84 ; 158 – 165, 2006
Sakurai Y, Shima M, Tanaka I, Fukuda K, Yoshida K, Yoshioka A. Association of antiidiotypic antibodies with immune tolerance induction therapy for hemophilia A with inhibitors. Haematologica 89 (6) ; 696 - 703, 2004
Hayashi T, Tanaka I, Shima M, Yoshida K, Fukuda K, Sakurai Y, Matsumoto T, Giddings JC, Yoshioka A. Unresponsiveness to factor VIII inhibitor bypassing agents during hemostatic treatment for life-threatening massive bleeding in a patient with hemophilia A and a high responding inhibitor. Haemophilia 10(4); 397 - 400, 2004
|
